Regenerative Medical Technology (RMTG) Cash from Discontinued Operations (2022)
Regenerative Medical Technology (RMTG) posted quarterly Cash from Discontinued Operations of 69463.0 for Q4 2022, up 29785.04% quarter-over-quarter from 234.0 in Q3 2022.
Regenerative Medical Technology (RMTG) Cash from Discontinued Operations (2022) Analysis & Trends
Regenerative Medical Technology's Cash from Discontinued Operations history runs 1 years deep, the most recent figure standing at 69463.0 for Q4 2022.
- In Q4 2022, Cash from Discontinued Operations changed N/A year-over-year to 69463.0; the TTM figure through Dec 2022 stood at 69713.0 (changed N/A YoY), while the FY2022 annual figure was 69713.0, up 627.85% from the prior year.
- Cash from Discontinued Operations for Q4 2022 stood at 69463.0, up from 234.0 in the prior quarter.
- The five-year high for Cash from Discontinued Operations was 69463.0 in Q4 2022, with the low at 234.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 69,463.00 |
| Dec 31, 2022 | 69,463.00 |
| Sep 30, 2022 | -234.00 |
| Sep 30, 2022 | -234.00 |
| Jun 30, 2022 | 408.00 |
| Jun 30, 2022 | 408.00 |
| Mar 31, 2022 | 76.00 |
| Mar 31, 2022 | 76.00 |